S. Park

发表

Multicenter phase II study of sunitinib in patients with non-clear cell renal cell carcinoma.

J. Ahn, D. Lee, Cheryn Song, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma.

J. Heo, T. Sohn, C. Park, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Mediastinal Lymphadenopathy in Pulmonary Fibrosis: Correlation with Disease Severity

S. Hahn, S. Park, S. Park, 2000, Journal of computer assisted tomography.

719PTUMOUR SHRINKAGE AT 6 WEEKS PREDICTS FAVORABLE CLINICAL OUTCOMES IN A PHASE III STUDY OF GEMCITABINE AND OXALIPLATIN WITH OR WITHOUT ERLOTINIB FOR ADVANCED BILIARY TRACT CANCER.

W. Kang, H. Kim, H. Lim, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized phase II study of irinotecan, leucovorin and 5-fluorouracil (ILF) versus cisplatin plus ILF (PILF) combination chemotherapy for advanced gastric cancer.

E. Cho, M. Chung, E. Nam, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Postoperative chemoradiotherapy for gastric cancer.

S. Choi, J. Heo, D. Lim, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

A randomized multi-center phase II trial of capecitabine (X) versus S-1 (S) as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer

Yoon-Koo Kang, J. Lee, Y. Min, 2007 .

Randomized phase II trial of neoadjuvant vs. adjuvant docetaxel plus cisplatin in patients with locally advanced gastric carcinoma: An interim analysis.

K. Ryu, C. Kim, J. Bae, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prediction of outcomes for patients with brain parenchymal metastases from breast cancer (BC): a new BC-specific prognostic model and a nomogram.

Sung-Bae Kim, J. Ahn, Yeon-Hee Park, 2012, Neuro-oncology.

MR characteristics of progressive massive fibrosis.

K. A. Kim, S. Hahn, S. Park, 2000, Journal of thoracic imaging.

Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+ gastric cancer patients

A. Bass, W. Park, T. Sohn, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

A multicenter, randomized phase III trial comparing second-line chemotherapy (SLC) plus best supportive care (BSC) with BSC alone for pretreated advanced gastric cancer (AGC).

I. Hwang, S. Oh, W. Kang, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Node-positive bladder cancer after neoadjuvant chemotherapy followed by radical cystectomy: A single-center retrospective study.

J. Cho, S. Park, J. Lee, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Nasal-type NK/T cell lymphoma: clinical features and treatment outcome

Keunchil Park, S. Lee, Y. Ko, 2005, British Journal of Cancer.

Phase II study of pazopanib monotherapy in metastatic gastroenteropancreatic neuroendocrine tumours

Kwhanmien Kim, H. Kim, J. Y. Choi, 2013, British Journal of Cancer.

A randomized, multi-center, open-label, phase II study of once-per-cycle DA-3031, a biosimilar pegylated G-CSF, compared with daily filgrastim in patients receiving TAC chemotherapy for early-stage breast cancer

S. Lee, J. Seo, H. Kwon, 2013, Investigational New Drugs.

AVAGAST: A randomized, double-blind, placebo-controlled, phase III study of first-line capecitabine and cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer (AGC).

M. Shah, E. Van Cutsem, A. Ohtsu, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Autologous peripheral blood stem cell transplantation with induction of autologous graft-versus-host disease in acute myeloid leukemia

S. Lee, C. Jung, W. Kang, 2003, Bone Marrow Transplantation.

Capecitabine monotherapy in patients with anthracycline-and taxane-pretreated metastatic breast cancer

C. Jung, J. Lee, S. Lee, 2004, Medical oncology.

gastrointestinal tumours, non-colorectalOlaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy: Phase III GOLD study

Y. Bang, D. Hodgson, S. Im, 2016 .

The need for ‘onco-nephrology’ is increasing in hematopoietic stem cell transplantation

J. Y. Lee, S. Hyun, Y. Ko, 2016, Bone Marrow Transplantation.

Phase I trial of all-trans retinoic acid in patients with treated head and neck squamous carcinoma.

B. Conley, D. V. Van Echo, R. Ord, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300

E. Van Cutsem, M. Alsina, M. Lichinitser, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Rapamycin-insensitive companion of mTOR (RICTOR) amplification defines a subset of advanced gastric cancer and is sensitive to AZD2014-mediated mTORC1/2 inhibition

S H Lee, W. Park, Jeeyun Lee, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Incidence of infection according to intravenous immunoglobulin use in autologous hematopoietic stem cell transplant recipients with multiple myeloma

J. Jang, S. Park, K. Kim, 2015, Transplant infectious disease : an official journal of the Transplantation Society.

Three-week schedule of irinotecan plus cisplatin in patients with previously untreated extensive-stage small-cell lung cancer

M. Ahn, S. C. Lee, I. Hwang, 2006, British Journal of Cancer.

A randomized, multi-center, open-label, phase III study of once-per-cycle DA-3031, a pegylated G-CSF, in comparison with daily filgrastim in patients receiving TAC chemotherapy for breast cancer

K. Jung, J. Seo, H. Kim, 2017, Supportive Care in Cancer.

MAP2K1 Mutation in Colorectal Cancer Patients: Therapeutic Challenge Using Patient-Derived Tumor Cell Lines

W. Kang, H. Lim, S. Park, 2017, Journal of Cancer.

Polymorphisms in the IL-13 and IL-4 R genes are associated with the development of renal cell carcinoma

J. Ahn, D. Lee, S. H. Lee, 2022 .

IMvigor130: Efficacy and safety from a phase III study of atezolizumab (atezo) as monotherapy or combined with platinum-based chemotherapy (PBC) vs placebo + PBC in previously untreated locally advanced or metastatic urothelial carcinoma (mUC)

M. Galsky, E. Kikuchi, I. Davis, 2019, Annals of Oncology.

Erdafitinib compared with vinflunine or docetaxel or pembrolizumab in patients (pts) with metastatic or surgically unresectable (M/UR) urothelial carcinoma (UC) and selected fgfr gene alterations (FGFRalt): The phase III THOR study.

R. Huddart, A. Santiago-Walker, A. Necchi, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

PD-L1 and immune infiltrates are differentially expressed in distinct subgroups of gastric cancer

J. Barrett, S. Park, D. Hodgson, 2018, Oncoimmunology.

697O A phase III, randomized, open-label study of first-line durvalumab (D) with or without tremelimumab (T) vs standard of care chemotherapy in patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE)

T. Powles, M. Galsky, A. Gupta, 2020 .

722PMOLECULAR SUBGROUP ANALYSIS OF CLINICAL OUTCOMES IN A PHASE 3 STUDY OF GEMCITABINE AND OXALIPLATIN WITH OR WITHOUT ERLOTINIB IN ADVANCED BILIARY TRACT CANCER.

W. Kang, H. Kim, Ho Yeong Lim, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

The value of CT-guided percutaneous needle aspiration in immunocompromised patients with suspected pulmonary infection.

S. Park, J. I. Jung, S. Hwang, 2000, AJR. American journal of roentgenology.

Efficacy and safety findings from DREAM: a phase III study of DHP107 (oral paclitaxel) versus i.v. paclitaxel in patients with advanced gastric cancer after failure of first-line chemotherapy

M. Ryu, S. Rha, B. Ryoo, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Altered distribution of Pneumocystis carinii pneumonia during radiation therapy

Y. S. Kim, S. Park, S. Kim, 1999, European Radiology.

CT differentiation of pneumonic-type bronchioloalveolar cell carcinoma and infectious pneumonia.

S. Park, B. Choi, M. Chung, 2001, The British journal of radiology.

Phase II study of sunitinib as second-line treatment in advanced biliary tract carcinoma: Multicenter, multinational study.

D. Doval, S. Thongprasert, J. Yi, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multicenter phase II study of sunitinib in patients with non-clear cell renal cell carcinoma.

J. Ahn, D. Lee, S. H. Lee, 2012 .

Malignant ectopic thymoma in the neck: a case report.

S. Park, S. Park, J. I. Jung, 1999, AJNR. American journal of neuroradiology.

Phase III study of gemcitabine/oxaliplatin (GEMOX) with or without erlotinib in unresectable, metastatic biliary tract carcinoma.

H. Jang, D. Shin, H. Jeung, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and efficacy of the oral CXCR4 inhibitor X4P-001 + axitinib in advanced renal cell carcinoma patients: An analysis of subgroup responses by prior treatment

T. Ho, M. Atkins, Siraj M. Ali, 2019, Annals of Oncology.

Comparison of the epidermal growth factor receptor gene mutation in matched primary tumor and lymph node metastasis of non-small cell lung cancer

I. Hwang, Byeong-Bae Park, K. Park, 2007 .

722PMOLECULAR SUBGROUP ANALYSIS OF CLINICAL OUTCOMES IN A PHASE 3 STUDY OF GEMCITABINE AND OXALIPLATIN WITH OR WITHOUT ERLOTINIB IN ADVANCED BILIARY TRACT CANCER.

H. Kim, Ho Yeong Lim, W. Kang, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

745P Patient-reported outcomes (PROs) from JAVELIN Bladder 100: Avelumab first-line (1L) maintenance + best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma (UC)

C. Tournigand, T. Powles, P. Grivas, 2020 .

MA21.10 Phase II Study of 160mg of Osimertinib in EGFR T790M Positive NSCLC with Brain or Leptomeningeal Metastases Who Progressed on Prior EGFR TKI

Jong-Mu Sun, K. Park, J. O. Park, 2019, Journal of Thoracic Oncology.

Second-line chemotherapy with mitomycin C and S-1 in patients with advanced gastric cancer.

E. Cho, S. Lee, D. Shin, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

698O Patient-reported outcomes (PROs) from IMvigor130: A global, randomised, partially blinded phase III study of atezolizumab (atezo) + platinum-based chemotherapy (PBC) vs placebo (PBO) + PBC in previously untreated locally advanced or metastatic urothelial carcinoma (mUC)

M. Galsky, E. Kikuchi, I. Davis, 2020 .

Incidence of infection according to intravenous immunoglobulin use in autologous hematopoietic stem cell transplant recipients with multiple myeloma

S. Park, C. Jung, Jun Ho Jang, 2015, Transplant infectious disease : an official journal of the Transplantation Society.

Randomized phase II study of PEP02, irinotecan, or docetaxel as a second-line therapy in gastric or gastroesophageal junction adenocarcinoma.

J. Tabernero, D. Cunningham, Y. Chao, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Three-week schedule of irinotecan plus cisplatin in patients with previously untreated extensive-stage small-cell lung cancer

M. Ahn, S. Park, B-B Park, 2006, British Journal of Cancer.